Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
BostonSportsNut Member Profile
Followed By 22
Posts 1,804
Boards Moderated 0
Alias Born 10/05/15
160x600 placeholder
BTIG Remains a Buy on Anavex Life Sciences (AVXL) TipRanks - 1/19/2022 1:45:28 AM
Anavex Life Sciences (AVXL) Gets a Buy Rating from H.C. Wainwright TipRanks - 1/11/2022 6:45:12 AM
JonesTrading Reaffirms Their Buy Rating on Anavex Life Sciences (AVXL) TipRanks - 1/10/2022 12:55:34 PM
Anavex Life Sciences Reports Positive Results from Phase 1 Clinical Trial of ANAVEX®3-71 GlobeNewswire Inc. - 1/10/2022 7:00:00 AM
Anavex Life Sciences Promotes Walter E Kaufmann, M.D. to Chief Scientific Officer and Appoints Edward R Hammond, M.D., M.P.H., Ph.D., as Chief Medical Officer GlobeNewswire Inc. - 1/6/2022 7:00:00 AM
Anavex Life Sciences Updates 2 Key Risk Factors TipRanks - 1/6/2022 6:01:37 AM
Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference GlobeNewswire Inc. - 1/5/2022 7:00:00 AM
Dawson James Maintains a Buy Rating on Anavex Life Sciences (AVXL) TipRanks - 1/5/2022 4:10:29 AM
Anavex Life Sciences to Present at 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. - 12/14/2021 7:00:00 AM
Anavex Life Sciences to Present at the 4th Annual Evercore ISI HealthCONx Conference GlobeNewswire Inc. - 11/29/2021 7:00:00 AM
Anavex Life provides key updates on clinical trials in rare genetic neurological disorders Seeking Alpha - 11/24/2021 9:40:36 AM
Anavex Life Sciences EPS misses by $0.39 Seeking Alpha - 11/24/2021 7:07:01 AM
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Year End Financial Results GlobeNewswire Inc. - 11/24/2021 7:00:00 AM
Notable earnings after Wednesday's close Seeking Alpha - 11/23/2021 5:35:23 PM
Anavex Life Sciences FY 2021 Earnings Preview Seeking Alpha - 11/23/2021 1:20:23 PM
Notable earnings before Wednesday's open Seeking Alpha - 11/23/2021 10:42:34 AM
Anavex Life Sciences to Announce Fiscal 2021 Year End Financial Results on Wednesday, November 24, 2021 GlobeNewswire Inc. - 11/17/2021 7:00:00 AM
Anavex Life Sciences Announces Participation at Upcoming Lausanne VIII Workshop Panel - Building Global Momentum for Interventions in Alzheimer’s Disease GlobeNewswire Inc. - 11/10/2021 7:00:00 AM
Anavex Life Sciences to Present at the Dawson James Securities 6th Annual Conference GlobeNewswire Inc. - 10/15/2021 7:00:00 AM
Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease GlobeNewswire Inc. - 10/13/2021 7:00:00 AM
Cassava down after phase 3 simufilam announcement; other Alzheimer's names follow Seeking Alpha - 10/6/2021 12:51:22 PM
CEO Presenting on the Emerging Growth Conference on September 29  Register Now InvestorsHub NewsWire - 9/28/2021 8:00:00 AM
Anavex Life Sciences Announces Participation at 5th Pharma Pricing, Reimbursement & Market Access 2021 GlobeNewswire Inc. - 9/27/2021 9:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/27/2021 8:11:01 AM
Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market® GlobeNewswire Inc. - 9/27/2021 7:00:00 AM
BostonSportsNut   Thursday, 12/08/16 03:06:47 PM
Re: None
Post # of 346506 

OC60: 9-MONTHS AND 12-MONTHS SAFETY AND EXPLORATORY EFFICACY DATA OF ANAVEX 2-73 IN A PHASE 2A STUDY IN MILD-TO-MODERATE ALZHEIMER’S DISEASE PATIENTS. Stephen Macfarlane1, Marco Cecchi2, Paul Maruff3, Kristina M Kapiak4, Christopher U Missling4 ((1) Caulfield Hospital, Melbourne, Australia; (2) Neuronetrix, Louisville, KY, USA; (3) Cogstate Ltd., Melbourne, Australia; (4)

Anavex Life Sciences Corp., New York, NY, USA)

Background: ANAVEX 2-73, a selective sigma-1 and muscarinic receptor agonist was tested in a Phase 2a study in patients with mild-to-moderate AD. Adverse Events (AEs) were recorded for assessment of safety and maximum tolerated dose (MTD), the Primary Endpoint of the study. Cognitive (MMSE, Cogstate, QEEG/ERP) and the functional (ADCS-ADL) marker were measured so as to establish a functional relationship between dosing regimen and exploratory efficacy outcomes, the Secondary Endpoint.

Methods: Thirty-two AD patients 55-85 years old with MMSE between 16 and 28 were recruited. After establishing the MTD and dose response in PART A of the trial, in PART B, all patients received ANAVEX 2-73 between 10mg and 50mg daily orally and re-assessed at 12, 26, 36, 48 weeks. For safety and MTD determination, mathematical modeling was fitted to the recorded AEs to establish the dose-risk relationship. For efficacy, statistical hypothesis tests were performed on cognitive and functional markers.

These functional markers were compared to the corresponding baselines.

Results: Safety: ANAVEX 2-73 demonstrated a favorable safety profile when administered to a clinical population of elderly AD patients with varying degrees of physical fragility. The most common side effects across all AE categories tended to be of mild severity grade 1, and were resolved with dose reductions that were anticipated within the adaptive design of the study protocol. Positive unexpected therapeutic response events, such as improved mood, improved social engagement and increased independent activities were recorded.

Exploratory Efficacy: 9-months and 12-months data of all available patients demonstrate that ANAVEX 2-73 preserves average MMSE and ADCS-ADL (PART B) scores across the entire patient group. ANAVEX 2-73 continues to show benefits over baseline for both Cogstate and QEEG/ERP.Conclusions: The safety of ANAVEX 2-73 was assessed and MTD was determined. Despite not optimal dosing in the longitudinal PART B of the study, both cognitive and functional performance is sustained over at least 9 months, suggesting that the effect of the compound does not seem to worsen AD symptoms with repeated dosing. In a disease state where progression is invariable over time, a stable MMSE and ADCS-ADL score is considered a positive outcome.

Population pharmacokinetic analysis is currently ongoing. The data collected so far support further clinical development of ANAVEX 2-73 and preparation for a larger confirmatory study is underway.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences